Mutengo Katongo H, Masenga Sepiso K, Mweemba Aggrey, Mutale Wilbroad, Kirabo Annet
HAND Research Group, School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia.
Schools of Public Health and Medicine, University of Zambia, Lusaka, Zambia.
Front Physiol. 2023 Apr 6;14:1075641. doi: 10.3389/fphys.2023.1075641. eCollection 2023.
The human gut microbiota environment is constantly changing and some specific changes influence the host's metabolic, immune, and neuroendocrine functions. Emerging evidence of the gut microbiota's role in the development of cardiovascular disease (CVD) including hypertension is remarkable. There is evidence showing that alterations in the gut microbiota and especially the gut-dependant metabolite trimethylamine N-oxide is associated with hypertension. However, there is a scarcity of literature addressing the role of trimethylamine N-oxide in hypertension pathogenesis. In this review, we discuss the impact of the gut microbiota and gut microbiota dependant trimethylamine N-oxide in the pathogenesis of hypertension. We present evidence from both human and animal studies and further discuss new insights relating to potential therapies for managing hypertension by altering the gut microbiota.
人类肠道微生物群环境不断变化，一些特定变化会影响宿主的代谢、免疫和神经内分泌功能。肠道微生物群在包括高血压在内的心血管疾病（CVD）发展过程中所起作用的新证据十分显著。有证据表明，肠道微生物群的改变，尤其是肠道依赖性代谢物氧化三甲胺与高血压有关。然而，关于氧化三甲胺在高血压发病机制中作用的文献却很匮乏。在本综述中，我们讨论了肠道微生物群以及肠道微生物群依赖性氧化三甲胺在高血压发病机制中的影响。我们展示了来自人类和动物研究的证据，并进一步讨论了通过改变肠道微生物群来管理高血压的潜在疗法的新见解。
